Literature DB >> 2137801

Role of insulin and atrial natriuretic peptide in sodium retention in insulin-treated IDDM patients during isotonic volume expansion.

R Trevisan1, P Fioretto, A Semplicini, G Opocher, F Mantero, S Rocco, G Remuzzi, A Morocutti, G Zanette, V Donadon.   

Abstract

Because insulin shows an antinatriuretic effect in healthy humans, insulin therapy resulting in circulating hyperinsulinemia may lead to sodium retention and in turn to hypertension in individuals with insulin-dependent diabetes mellitus (IDDM). Moreover, it has been proved that atrial natriuretic peptide (ANP) plays a major role in modulating natriuresis in humans. This study investigated the relationship between insulin and ANP in modulating sodium metabolism in normotensive and hypertensive IDDM subjects compared with control groups of normotensive and hypertensive nondiabetic subjects. IDDM normotensive and hypertensive subjects had mean +/- SE duration of IDDM of 7 +/- 2 and 8 +/- 2 yr, respectively, and had no clinical features of diabetic nephropathy. All subjects received a saline infusion (2 mmol.kg-1.90 min-1) during euglycemia. IDDM normotensive and hypertensive subjects received a subcutaneous insulin infusion (15 mU.kg-1.h-1), resulting in twofold higher plasma free-insulin levels (16 +/- 2 and 19 +/- 3 microU/ml, respectively) than in nondiabetic normotensive and hypertensive subjects (7 +/- 2 and 8 +/- 2 microU/ml, respectively). During saline challenge, sodium excretion increased by 22 +/- 4% in normotensive and 49 +/- 9% in hypertensive nondiabetic subjects but by only 11 +/- 0.4% in normotensive (P less than 0.01) and 8 +/- 2% in hypertensive (P less than 0.01) IDDM subjects. The impaired natriuretic response to saline challenge was mainly due to greater rates of sodium reabsorption by kidney proximal tubules in IDDM than nondiabetic subjects. At baseline, plasma ANP concentrations were significantly higher in both IDDM groups than in control groups (normotensive IDDM and control subjects: 38 +/- 4 and 19 +/- 2 pg/ml, respectively, P less than 0.01; hypertensive IDDM and control subjects: 45 +/- 6 and 27 +/- 4 pg/ml, respectively, P less than 0.05). After saline challenge, ANP concentrations rose to 39 +/- 4 pg/ml in normotensive and 49 +/- 5 pg/ml in hypertensive control subjects, whereas no significant change above baseline value was seen in IDDM subjects. Both IDDM groups showed a 10-12% greater exchangeable Na+ pool than control subjects regardless of the presence of hypertension. Subcutaneous insulin infusion, resulting in circulating plasma free-insulin levels in normotensive control subjects comparable to those in IDDM patients, inhibited natriuresis, increased proximal tubule sodium reabsorption at the level of the kidney, and inhibited an adequate ANP stimulation by saline challenge. We conclude that hyperinsulinemia leads to increased proximal tubule sodium reabsorption and impaired ANP response during saline administration. Both mechanisms account for sodium retention in normotensive and hypertensive IDDM patients.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137801     DOI: 10.2337/diab.39.3.289

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  28 in total

1.  Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects.

Authors:  P Stenvinkel; J Bolinder; A Alvestrand
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

2.  Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus.

Authors:  G C Viberti; R Trevisan; R Nosadini
Journal:  Diabetologia       Date:  1991-01       Impact factor: 10.122

Review 3.  Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure.

Authors:  Chaitanya Madamanchi; Hassan Alhosaini; Arihiro Sumida; Marschall S Runge
Journal:  Int J Cardiol       Date:  2014-08-09       Impact factor: 4.164

4.  Lack of evidence of hypervolemia in children with insulin-dependent diabetes mellitus.

Authors:  Ann Raes; Sarah Van Aken; Margarita Craen; Raymond Donckerwolcke; Johan Vande Walle
Journal:  Pediatr Nephrol       Date:  2006-11-09       Impact factor: 3.714

Review 5.  Insulin resistance and hypertension--implications for treatment.

Authors:  P A Rutherford; T H Thomas; R Wilkinson
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

6.  Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals.

Authors:  Susan Cheng; Caroline S Fox; Martin G Larson; Joseph M Massaro; Elizabeth L McCabe; Abigail May Khan; Daniel Levy; Udo Hoffmann; Christopher J O'Donnell; Karen K Miller; Christopher Newton-Cheh; Andrea D Coviello; Shalender Bhasin; Ramachandran S Vasan; Thomas J Wang
Journal:  Am J Cardiol       Date:  2011-08-01       Impact factor: 2.778

7.  Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice.

Authors:  H Makino; M Mukoyama; K Mori; T Suganami; M Kasahara; K Yahata; T Nagae; H Yokoi; K Sawai; Y Ogawa; S Suga; Y Yoshimasa; A Sugawara; I Tanaka; K Nakao
Journal:  Diabetologia       Date:  2006-08-18       Impact factor: 10.122

8.  Effects of insulin and lipid emulsion on renal haemodynamics and renal sodium handling in IDDM patients.

Authors:  T Pelikánová; I Smrcková; J Krízová; J Stríbrná; V Lánská
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

9.  Increased prevalence of salt sensitivity of blood pressure in IDDM with and without microalbuminuria.

Authors:  K Strojek; W Grzeszczak; B Lacka; J Gorska; C K Keller; E Ritz
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

10.  Impaired response to angiotensin II in type 1 (insulin-dependent) diabetes mellitus. Role of prostaglandins and sodium-lithium countertransport activity.

Authors:  P Fioretto; M Sambataro; M G Cipollina; E Duner; C Giorato; A Morocutti; F Mollo; G P Ben; A Carraro; D Sacerdoti
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.